Avenue Therapeutics, Inc. (ATXI)
NASDAQ: ATXI · Real-Time Price · USD
1.900
-0.040 (-2.06%)
Dec 3, 2024, 1:55 PM EST - Market open
Avenue Therapeutics Employees
Avenue Therapeutics had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$6,092,667
Market Cap
3.63M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
iCoreConnect | 70 |
iSpecimen | 53 |
Healthcare Triangle | 31 |
ReShape Lifesciences | 29 |
Theriva Biologics | 22 |
Azitra | 10 |
Galmed Pharmaceuticals | 8 |
Protagenic Therapeutics | 3 |
ATXI News
- 18 days ago - Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 7 weeks ago - Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit - GlobeNewsWire
- 3 months ago - Avenue Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 5 months ago - Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - GlobeNewsWire
- 7 months ago - Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - GlobeNewsWire
- 7 months ago - Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 7 months ago - Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds - GlobeNewsWire